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Abbreviations 
 
3D-CRT  three-dimensional conformal radiotherapy   
ADT   androgen deprivation therapy 
APCs   antigen presenting cells 
approx.  approximately  
BMI   body-mass-index 
CD4+   cluster of differentiation 4 positive 
CD8+   cluster of differentiation 8 positive  
CRPC   castration resistant prostate cancer 
CSPC   castration sensitive prostate cancer 
CT    computed tomography 
CTLA4  cytotoxic T-lymphocyte associated protein 4 
CYP17  cytochrome P450 17 
DCs   dendritic cells 
DNA   deoxyribonucleic acid 
DRE   digital rectal examination 
EBRT   external beam radiotherapy 
e.g.   exempli gratia (for example) 
EMP   estramustine phosphate 
FDA   Food and Drug Administration 
FDG    fluordesoxyglucose 
GM-CSF  granulocyte macrophage colony-stimulating factor 
GS   Gleason Score 
Gy   Gray 
HDR   high dose radiation 
HLA   human leukocyte antigen 
IFN-ɣ   interferon gamma 
IMRT   intensity-modulated external beam radiotherapy 
LDR   low dose radiation 
LHRH   luteinizing hormone-releasing hormone 
MDSCs   myeloid-derived suppressor cells  
MHC   major histocompatibility complex 
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MRI   magnetic resonance imaging 
n.a.   not applicable 
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PCSA   prostate stem cell antigen 
PD-1   programmed cell death protein 1 
PET-CT   positron emission tomography–computed tomography 
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PSA   prostate specific antigen 
PSMA   prostate specific membrane antigen 
RCC   renal cell carcinoma 
RNA   ribonucleic acid 
RP   radical prostatectomy 
STEAP1   six transmembrane epithelial antigen of the prostate 1 
TAA   tumor associated antigen 
TGF-ß1  transforming growth factor beta 1 
TNF   tumor necrosis factor 
TRP-P8   transient receptor potential p8 
TRUS   transrectal ultrasound 
TTP   time to progression 
VEGF   vascular endothelial growth factor 
vs.   versus 
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Introduction 
 
1. Prostate cancer 
 
1.1 Epidemiology 
 
The medical community has increased the amount of attention paid to prostate 
cancer in recent decades. Due to its socioeconomic impact and the 
demographical development in industrial countries, the subject has gained 
much importance and interest in researching new therapies for this disease is 
rising. Prostate cancer is the leading tumor entity among men in Germany and 
the third most common cause of cancer related death. The incidence in 
Germany was 65 800 cases in 2010, for 2014 it has been calculated to be 
approximately 70 100 [1]. It is the second most common cause of cancer 
related death among men in the United States of America. In Europe it 
constitutes 11% of all cancer cases in men [2], with an estimated 2,6 million 
patients diagnosed yearly. The mean age for diagnosis is 69 years, which is 
also the mean age for cancer diagnosis in Germany [1].  
 
The 5-year-survival rate for the disease has improved considerably in the last 
35 years. Men diagnosed at the beginning of the 1980s had a five-year-survival 
rate of 70%, whereas men who were diagnosed between 2000 and 2004 had a 
five-year-survival-rate of 87% [3]. This improvement is most likely explained by 
the preventive measures for detecting the disease and as a result the now 
much earlier time of diagnosis. 
 
1.2 Histology 
 
Prostate cancer is in 95% of the cases an adenocarcinoma [4], which sprouts 
from the epithelial cells that make up the glandules. Non adenocarcinomas 
generally have their origin in the transitional epithelial cells from urothelium, the 
tissue that covers the inside of the urethra and the bladder. Other tumor types 
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like lymphoma, neuroendocrine tumors and sarcoma develop very rarely in the 
prostate [5].  
 
1.3 Risk factors 
 
Among the most important risk factors for prostate cancer is age. Men under the 
age of 40 rarely develop this tumor [6]. The hereditary factor also plays an 
important role. Provided a first-line relative suffers from the disease, the risk for 
the person in question to become sick is at least doubled. When two or more 
first-line relatives develop the disease, the risk rises to 5-11 times more than a 
person with no familial history of prostate cancer [7]. Other factors such as taller 
height, smoking history, high caloric diet and higher BMI elevate the risk for a 
fatal prostate cancer. On the other hand, high physical activity levels correlate 
with lower prostate cancer risk [8]. 
 
1.4 Diagnosis 
1.4.1 Screening 
PSA level measures and digital rectal examination (DRE) are established 
screening methods for prostate cancer in clinical practice. The goal of early 
detection measurements is to detect the disease in a local stage, since this is 
the only way to treat the patient with a curative approach. In Germany, men 
from the age of 40 and below 70 are advised to submit themselves to this 
screening [9]. Although it seems reasonable to perform these tests routinely it is 
important to point out that none of them have shown to reduce mortality from 
prostate cancer [10]. 
 
1.4.1.1 Prostate specific antigen 
The prostate-specific antigen (PSA, also known as kallikrein-3 (KLK3) and 
gamma-seminoprotein) is a serine peptidase enzyme secreted almost 
exclusively by the epithelial cells of the prostate, and can be measured in low 
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quantities in healthy male serum. Its physiological function is to liquefy the 
semen. PSA is an organ-specific but not tumor specific marker; other processes 
in the prostate for example a prostatitis, prostate adenoma or rectal 
manipulation of the prostate in a DRE can elevate PSA levels. Therapies with 
steroids or 5-alpha-reductase inhibitors can create false low PSA levels.  
A PSA value higher than 4 ng/ml is considered suspicious and requires a further 
test for confirmation before proceeding with more diagnostics. The probability of 
diagnosing prostate cancer through an elevated PSA level depends on how 
much this value has risen in the patient’s serum. The positive predictive value of 
PSA measurements for prostate cancer is of approx. 10% at a PSA level of  
0.6-1.0 ng/ml, of  27% at a PSA level of 3.1-4.0 ng/ml and 41% for a PSA level 
of 4.0-10.0 ng/ml [11]. Though very rare, it is worth mentioning that there are 
certain prostate cancers that do not present a PSA elevation and can therefore 
pass unnoticed when merely assessing the PSA blood level. The Prostate 
Cancer Prevention Trial from the National Cancer Institute showed that 15% of 
patients who presented normal PSA levels indeed had prostate cancer [12]. 
The majority of PSA is bound to serum-proteins, the so called total PSA. The 
fraction of PSA unbound is called free PSA. The ratio of free PSA to total PSA 
is important for evaluating the risk of the presence of prostate cancer. In the 
case of a free PSA/total PSA ratio of less than 20%, the probability of a tumor is 
elevated. This has proven to be useful to assess the risk for cancer when PSA 
levels are elevated in a range between 4-10 ng/ml: a study showed that 56% of 
men who had PSA levels between 4 and 10 ng/ml and a free PSA/total PSA 
ratio of > 0.1 were diagnosed with prostate cancer after submitting themselves 
to ultrasound-guided biopsies, whereas only 8% of the men with PSA levels in 
the same range and a ratio of > 0.25 were diagnosed with the disease [13]. 
How PSA levels behave is also interesting for predicting the development of the 
disease. Men who had a PSA level rise of more than 2,0 ng/ml during the year 
before the disease was diagnosed present a higher risk of death caused by 
prostate cancer. Undergoing radical prostatectomy had no influence on the 
prognosis of these patients [14]. 
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Nowadays routine PSA measures have led to the detection of several prostate 
cancer cases which otherwise would have possibly gone unnoticed. According 
to estimations of the Robert Koch Institute, approximately 90% of the prostate 
cancer diagnoses are achieved throughout elevated PSA levels, and 50% of 
these would have probably remained undiscovered if not for PSA screening [3]. 
Before PSA was used as a screening method, 33% of the patients at the time of 
diagnosis had already developed metastases. This number has shrunk now to 
7%. The use of PSA as a screening method has caused some controversy 
though, given that it elevates the risk of overdiagnosis, and as a consequence 
overtreatment. It is estimated that between 23-42% of the prostate cancers 
detected via elevated PSA levels would have otherwise remained unnoticed 
throughout the patient’s life [15]. Since prostate cancer regularly develops 
slowly and the patients get sick from it at advanced ages, many cases would 
probably not cause any symptoms and remain undiagnosed, and these patients 
would die from a different cause. With routine PSA screening, these patients get 
treatment and suffer from a variety of side effects, most commonly urinary 
incontinence and erectile dysfunction, causing unnecessary decline in life 
quality [16]. 
 
1.4.1.2 Digital rectal examination  
The digital rectal examination is a cost-efficient, easy to conduct and quick way 
to inspect the prostate. Its size and consistency can be examined and the 
examination provides an overview of the surrounding tissue and organs. The 
part of the prostate that can be palpated is the peripheral lobe. Nearly three 
quarters of the tumors generate in this area. However, the sensitivity of DRE for 
detection of PC is limited and below 40% [17]. A normal palpation result does 
not guarantee a tumor absence, since a part of the prostate cannot be felt by 
the examiner, and the ability to perform the examination thoroughly and 
accurately varies among the medical community [18]. Nevertheless, DRE is an 
important part of the early detection process for prostate cancer and it definitely 
cannot be replaced by merely examining PSA levels.  
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1.4.2 Imaging 
1.4.2.1 Transrectal ultrasound  
Transrectal sonography (TRUS) has become a standard procedure for the 
detection of prostate cancer. The TRUS provides a morphologic overview of the 
prostate and the surrounding tissues. However, it is not a very sensitive 
procedure, since the probability of identifying a tumor lies between 17 and 57%, 
and 39% of the prostate tumors cannot be differentiated from regular gland 
tissue [19]. In combination with DRE and PSA though, it can provide significant 
information on the potential presence of a tumor and the tumor extent. TRUS is 
an important tool for tumor staging as it allows the examiner to assess to what 
extent the tumor has infiltrated the prostate capsule. It also plays an vital role for 
therapeutic indications such as brachytherapy and cryotherapy. 
 
1.4.2.2 Magnetic Resonance Imaging 
Magnetic Resonance Imaging (MRI) has a good sensitivity for detection of PC 
ranging between 60-90% for detecting a tumor [20]. New techniques such as 
dynamic contrast-enhanced MRI suggest that its specificity for detecting PC 
ranges 88% [21], though false positive results can occur due to bleeding after 
TRUS guided biopsy or prostatitis [22]. The most common indication for using 
MRI is a continuing rise of PSA values in spite of a negative result in the TRUS 
guided biopsy. Studies show that about a third of the patients with one or more 
negative biopsy results were finally diagnosed with prostate cancer through MRI 
[23, 24]. For staging purposes, it is also very accurate in showing extra-capsular 
growth of the tumor or seminal vesicle invasion and enlarged abdominal or 
pelvic lymph nodes. In some cases MRI can also be used for performing a MRI 
guided biopsy [25]. 
 
1.4.2.3 Biopsy 
Nowadays there are several different ways to perform a prostate biopsy. The 
standard way for a first time prostate histologic examination is the ultrasound 
guided biopsy [26], which can be performed through the perineum, transrectal 
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or through the urethra, transrectal being the most common approach. The 
principle behind it is to identify the organ with the ultrasound, take 
systematically 12 samples from different parts of the organ which are then 
examined under the microscope. A study examining different biopsy schemes 
and their tumor detection rates indicated that the 12-sample biopsy was better 
than the other schemes with a detection rate of 44,4% [27]. The TRUS guided 
biopsy does not detect every tumor, so a negative biopsy does not guarantee 
the absence of a tumor. It is estimated that approximately a quarter of the initial 
TRUS guided biopsies present a false negative result [28]. These patients 
usually undergo second or further biopsies when PSA values continue to rise. 
To improve these numbers other methods have been developed that could 
provide results. The MRI-guided biopsy presents the advantage that the tumors 
are more likely identified with MRI than TRUS, so the biopsy can be taken from 
suspicious parts of the gland instead of “blindly”. There appears to be a higher 
correlation between MRI guided biopsy and the definite pathology results, than 
TRUS guided biopsy [29]. Fusion MRI which combines MRI with TRUS guided 
biopsy also seems to have promising results showing a high accuracy at 
detecting prostate cancer [30]. 
 
1.4.3 Staging and risk stratification 
1.4.3.1 Gleason Score 
The Gleason Score (GS) [31] has become the standard classification to 
determine the grade of differentiation of prostate cancer tissue. Moreover, it is 
one of the main prognostic parameters for prostate cancer. The prostate tissue 
is evaluated microscopically assessing the morphology and architecture of the 
glandular structures. The pathologist assesses the two most common patterns 
in the tissue and the numbers are added, so that the GS ranges between 2 and 
10 possible points [32]. The Gleason score’s predictive value only applies to the 
naïve, primary prostate cancer (before radiation or hormone therapy) and is 
only partially applicable for metastases or secondary tumors. 
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1.4.3.2 TNM classification 
The TNM classification allows an objective assessment of the local and 
systemic extent of prostate cancer. It can be differentiated between a clinical 
stage (cT, cN) and a pathologic stage (pT, pN) depending on the method 
applied to determine the T and N-stage. According to the National 
Comprehensive Cancer Network (NCCN) [33], the TNM classification for 
prostate cancer reads as follows: 
 
Table 1. TNM classification for prostate cancer according to the National 
Comprehensive Cancer Network (NCCN) clinical practice guidelines in 
Oncology [33]. 
 
T  Primary Tumor 
TX Tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent tumor not palpable or visible by imaging 
 T1a Tumor incidental histological finding in 5% or less of tissue 
resected 
T1b Tumor incidental histological finding in more than 5% of tissue 
resected 
T1c Tumor identified by needle biopsy (e.g. because of elevated 
prostate-specific level) 
T2 Tumor confined within the prostate 
 T2a Tumor involves one half of one lobe or less 
T2b Tumor involves more than half of one lobe, but not both lobes 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule 
 T3a Extracapsular extension (unilateral or bilateral) including 
microscopic bladder neck involvement 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than 
seminal vesicles: external sphincter, rectum, levator muscles, 
and/or pelvic wall 
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N  Regional lymph nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph  node metastasis 
N1 Regional lymph  node metastasis 
M  Distant metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 M1a Non-regional lymph node(s) 
M1b Bone(s) 
M1c Other site(s) 
 
1.4.3.3 Risk stratification according to D’Amico 
The risk stratification of D’Amico [34] separates PC into three groups using 
PSA-value, Gleason score and cT-stadium. These values are predictors for the 
outcome of PC, and determine the risk of death from prostate cancer after 
radical prostatectomy [35].  
 
Table 2. Risk stratification for prostate cancer according to D’Amico [34].  
 
Risk PSA level Gleason score T-stadium 
Low risk PSA < 10 ng/ml GS ≤ 6 cT1-2a 
Intermediate risk PSA 10-20 ng/m GS  7 cT2b 
High risk PSA > 20 ng/ml GS > 7 cT2c-3a 
 
 18 
 
1.4.4 Imaging Methods for clinical staging 
1.4.4.1 Bone scan 
The bone scan is used for staging purposes in prostate cancer because bone 
metastases are most common for this particular tumor. This scan has a very 
high sensitivity and negative predictive value [36], but not a very good 
specificity. A meta-analysis performed by Abuzallouf et al. suggests that the 
diagnostic value of the bone scan greatly correlates with the PSA level [37]. 
Apparently its diagnostic value is also highly dependent on the Gleason Score 
and the clinical stage of the disease [38]. Thus, according to the literature, a 
bone scan should not be performed on asymptomatic patients if they do not 
meet following criteria: GS of minimum 8 or clinical stage above T3, PSA level 
>10 ng/ml [39] or even >20 ng/ml [40]. Nevertheless the presence of symptoms 
(such as pain or pathological fractures) is a definite indication for a screening 
via bone scan. 
 
1.4.4.2 MRI 
See 1.4.2.2 above. 
1.4.4.3 Computer tomography and positron emission tomography–computed 
tomography scan 
Both computer tomography (CT-scan) and positron emission tomography–
computed tomography scan (PET-CT) play a secondary role for the initial 
diagnosis and staging of prostate cancer. Data support that in case of a PSA 
lower than 20 ng/ml and a Gleason score of less than 7, it is rare to identify any 
pathologies in the prostate using computed tomography. Therefore, CT is not 
recommended as a standard imaging method in the staging of clinically 
localized prostate cancer. Nowadays, hybrid imaging methods such as PET-CT 
are gaining increasing importance as they allow both a morphologic and a 
functional assessment.  PET-CT presents a promising possibility to track down 
metastases. However, the majority of PET-CTs are performed in order to detect 
potential local tumor recurrences [41]. The several tracers used, for example 
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FDG (F-18-fluorodeoxyglucose) and 11-C-Choline[42] present different but 
promising results for improving the care of patients with PSA recurrence. 
 
1.5 Therapy 
1.5.1 Therapy of localized prostate cancer  
1.5.1.1 “Active surveillance” 
As mentioned before, the incidence of prostate cancer has risen mostly due to 
PSA screening, revealing prostate cancers that in many cases are overtreated. 
According to a study by Godtman et al. approximately 45% of the patients 
diagnosed with prostate cancer through PSA screening apply as candidates for 
conservative therapy [43]. The concept of active surveillance was developed in 
to prevent this excessive treatment and loss of life quality, but still remains a 
curative approach. Applicable only for men with low risk disease (according to 
D’Amico et al. [34, 44]), it involves sequential serum PSA assessments and 
clinical assessments (DRE). One year after diagnosis, patients undergo a 
repeat biopsy to detect any changes in tumor differentiation or extent.  In case 
of a tumor progression, the patients are mostly advised to undergo curative 
treatment such as prostatectomy or radiotherapy. Current studies show that 
within 5 years of active surveillance, less than 50% of patients require definitive 
radical treatment [45].  
 
1.5.1.2 Brachytherapy  
LDR-brachytherapy is a procedure to implant a radioactive seed into the 
prostate through the perineum under ultrasound control. The dosage can be 
accurately calculated so that only the prostate gland receives radiation, and the 
rectum and urethra remain unaffected. Until now, this type of therapy has been 
only recommended for low risk prostate cancers (a PSA of under 10 ng/dl and a 
Gleason score of under 7 are mostly required as eligibility criteria) [46, 47], 
though some studies suggest that the outcome is equally effective for patients 
with a moderate or high risk prostate cancer. The LDR-brachytherapy shows a 
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recurrence-free survival of 71-93% after 5 years, and 65-85% after 10 years 
[48-50]. It is difficult to interpret these results since there are no randomized 
studies comparing LDR-brachytherapy with other treatment options for localized 
prostate cancer. 
The high dose rate brachytherapy (HDR-brachytherapy) or non-permanent 
transperineal interstitial prostate brachytherapy is another option for the 
treatment of localized prostate cancer. After external radiation with a dose 
between 50-60 Gy, the patient receives extra radiation directly in the prostate 
using a needle with a highly radioactive nuclide, thus achieving a total radiation 
dose of 100-130 Gy. According to a trial by Hoskin et al. the combination of 
HDR-brachytherapy and external beam radiation therapy (EBRT) shows a 
significant improvement in the quality of life and the recurrence free survival 
compared to EBRT alone [51]. However, only a small proportion of patients with 
prostate cancer is treated by HDR brachytherapy.  
 
1.5.1.3 Radical prostatectomy 
Radical prostatectomy (RP) is considered the gold standard curative treatment 
for localized prostate cancer for patients with a life expectancy of at least 10 
years. A radical prostatectomy can be performed through several ways: 
retropubic, perineal, laparoscopic and robot-assisted laparoscopic. Regardless 
of the approach, the procedure aims to remove the whole organ, the two 
seminal vesicles and surrounding tissue (often also with a bilateral pelvic lymph 
node dissection).  It remains the only form of therapy that has proven to reduce 
the rate of death from prostate cancer compared to conservative treatment, 
according to Bill-Axelson et al. [52-54]. However, there is no clear evidence that 
it provides improved oncologic outcome compared to radiotherapy.  The two 
most common complications of RP are incontinence and impotence. Data 
suggest that if performed correctly, 12 months post-surgery the mean 
continence rate is 80-97% [55] with a mean potency recovery rate of 26-63% 
[56]. It is still unclear whether robotic-assisted prostatectomy provides an 
advantage over open prostatectomy regarding functional outcome. Small cohort 
trials propose that robotic prostatectomy performs better with regards of blood 
 21 
 
loss and hospitalization time [57]. According to a study by Bianco et al. though, 
RP does seem to improve patients’ prognosis: a study analyzed the data of 
1045 patients who had undergone radical prostatectomy and found that the 10-
year survival rate for cancer-specific survival was of 92%, for metastasis-free-
survival of 91% and for PSA progression-free-survival of 75% [58]. 
 
1.5.1.4 External radiotherapy  
Radiotherapy is a curative treatment option for prostate cancer, though benefits 
regarding overall survival or decrease in mortality from prostate cancer have not 
yet been proven. Although there are no randomized studies, many data suggest 
that radiotherapy is equally effective as radical prostatectomy for treating PC 
and that the quality of life after treatment is also better after radiation than after 
surgery [59]. Several techniques, such as three-dimensional conformal 
radiotherapy (3D-CRT) and intensity-modulated external beam radiotherapy 
(IMRT), have been developed in order to minimize radiation of the prostate 
surrounding tissue, preventing the numerous gastrointestinal and genitourinary 
complications of this treatment. A meta-analysis comparing radical 
prostatectomy with several radiation forms showed that men who submitted 
themselves to radiation only in comparison to RP presented less erectile 
dysfunction problems [60]. Radiotherapy presents a good alternative for 
patients who do not wish to undergo surgery, or in cases where any 
contraindications for the operation exist. 
 
1.5.2 Therapy of hormone sensitive prostate cancer 
1.5.2.1 Hormonal therapy 
Testosterone and other androgenic substances physiologically stimulate the 
growth and proliferation of prostate cells. In the presence of PC, testosterone 
has the same effect on tumorous cells. The majority of this hormone is 
produced in the testicles, a small amount in the adrenal gland. The aim of 
hormone therapy is to stop the stimulation of androgens on the malignant cells 
since without testosterone tumor cells undergo apoptosis. There are several 
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ways to accomplish this, but in general they can be summarized under the 
concept of androgen depriving therapy (ADT). Androgen deprivation can be 
performed by either inhibiting the secretion of the hormones from the testicles 
(surgical orchiectomy, LHRH-agonists, LHRH-antagonists), or preventing the 
hormones from docking on their respective receptors (steroidal- and non-
steroidal-antiandrogens). The combination of both strategies is known as total 
androgen blockade. 
 
The decision to begin with ADT must be thoroughly weighed and made 
cautiously. Until the present day no studies have been able to prove that ADT 
does indeed improve cancer specific survival [61]. The lack of evidence must be 
taken into account since ADT causes many adverse effects that have an impact 
on the patients’ quality of life [62]. The different treatment plans have diverse 
side effects, but the most common are: hot flashes, erectile dysfunction and 
loss of libido [63]. Other side effects include cardiovascular diseases, metabolic 
syndrome, impaired glucose tolerance and accelerated loss of bone mineral 
density. There is also no significant gain in overall survival if ADT is begun at a 
point where metastases are asymptomatic in comparison to commencing when 
metastases are symptomatic [64]. Since there is no optimal timing to begin with 
ADT, the indication to proceed should be stated on an individual basis for each 
patient. There are different opinions as to what kind of scheme should be used 
as first-line therapy. Bilateral orchiectomy is under local anesthesia a relatively 
simple to perform procedure that quickly achieves androgen deprivation [65]. 
Many men do not feel comfortable with it though, so most patients prefer 
chemical castration. LHRH (luteinizing hormone-releasing hormone) agonists 
are currently the most frequently used for ADT. They present a great advantage 
which is that they can be applied as depot injections on a monthly up to yearly 
basis. Both orchiectomy and LHRH agonists are adequate first line treatments 
at the beginning of hormone therapy [64, 66]. LHRH antagonists such as 
Abarelix and Degarelix successfully achieve chemical castration, though they 
are less used than LHRH agonists. Non-steroidal antiandrogens (Bicalutamide, 
Flutamide, Nilutamide) do not suppress testosterone levels, so sexual 
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dysfunction and bone problems do not seem to be a trouble [67] compared to 
the above mentioned castration therapies and steroidal antiandrogens. The 
concept of complete androgen blockade includes both the inhibition of systemic 
testosterone by LHRH-agonists and the blockade of the androgen receptor by a 
steroidal or non-steroidal androgen-receptor-inhibitor (such as bicalutamide). 
The survival benefit achieved by this strategy is low and therefore it is not 
recommended as standard-of-care [68]. However, to prevent a flare 
phenomenon, most patients receive complete androgen blockade during the 
first weeks of androgen deprivation therapy [69].  
 
1.5.2.2 Progression into castration resistant prostate cancer 
ADT, although effective for prolonging PSA relapse free survival and delaying 
complications such as ureteral obstruction or skeletal related events, is not a 
curative treatment, and disease progression will happen after a certain amount 
of time. Estimations suggest that first line therapy in form of orchiectomy, LHRH 
agonists or antagonists, or antiandrogens has a response rate of a 100% and a 
mean response duration of 36-48 months [70]. Eventually, the effect of this 
therapy wears off, and secondary hormone manipulation strategies can be 
recommended. One option in these patiens is a maximal androgen blockade, 
which has a response rate of 60-80% and a response duration of approximately 
6-8 months [71]. When a maximal androgen blockade ceases to work, the 
subsequent form of therapy varies from patient to patient since multiple facts 
should be taken into consideration (from the will of the patient, to symptoms and 
stage of the disease). The pathophysiology behind the progression from 
hormone sensitive into castration resistant PC has not been entirely clarified, 
though there are some approaches that could explain this development such as 
ligand independent activation of the androgen receptor [72, 73]. 
 
1.5.3 Therapy of castration resistant prostate cancer  
Castration resistant prostate cancer (CRPC) is defined by a radiologic 
progression (new bone or soft tissue metastatic lesions) or multiple subsequent 
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increases of the PSA despite a testosterone level lower than 50 ng/dL [74]. The 
main endpoint in most phase III trials assessing new therapies for CRPC is 
overall survival. Improvement in quality of life, although not as easily measured, 
is also important for palliative treatment of PC. 
 
1.5.3.1 Docetaxel and cabazitaxel chemotherapy 
Docetaxel is currently the standard therapy for CRPC. It shows a moderate 
prolongation in overall survival of approximately 2-2,5 months against 
mitroxantone+prednisone [75, 76]. The most beneficial application seems to be 
docetaxel combined with prednisone every three weeks. Indications for a 
docetaxel chemotherapy are mostly tumor related pain and a rapid PSA-
doubling time (< 3 months). This therapy seems more profitable for patients with 
a good Karnofsky-Index and no visceral metastases [77]. Adverse effects 
include neutropenia, skin conditions such as exanthema and nail malformations, 
neuropathy, among others. 
 
The TROPIC trial was a randomized phase III trial that compared cabazitaxel 
plus prednisone against mitoxantrone + prednisone. The men engaged in the 
trial were all CRPC patients who had suffered progression under docetaxel 
treatment. The primary endpoint was overall survival, and the cabazitaxel group 
showed a benefit of 2,4 months. The cabazitaxel group also showed an 
improvement for the secondary endpoints which were progression free survival, 
PSA response and treatment response [78]. This group also showed more 
adverse effects than the control group, especially hematological side effects. 
 
1.5.3.2 Enzalutamide 
Enzalutamide works by blocking nuclear translocation and transcription 
processes and androgen-binding receptors. In 2012 data from the AFFIRM 
study were published with promising results for enzalutamide. The trial enrolled 
1199 patients with CRPC who had progressed after docetaxel therapy. Its 
primary endpoint was overall survival, where the enzalutamide showed a 
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significant benefit of 18,4 months over 13,6 from the placebo arm [79]. It also 
showed better results for the enzalutamide group regarding PSA value, quality 
of life, time to PSA progression and soft tissue response. 
In patients with chemotherapy-naïve CRPC, Enzalutamide has been shown to 
decrease the risk of radiographic progression and death [80]. 
 
1.5.3.3 Abiraterone 
Arbiraterone acetate is a CYP17 inhibitor and thereby blocks both intraadrenal, 
intratesticular and intraprostatic androgen production and is applied once a day 
in combination to prednisone. Similarly to enzalutamide, it showed promising 
results in a phase III trial (COU-AA-301 trial) where 1195 patients were 
randomly divided into an abiraterone and a placebo group. In this trial all 
patients also had a CRPC and had suffered progression during or after 
docetaxel treatment. The study showed an overall survival of 15,8 months for 
abiraterone versus 11,2 for the placebo group [81, 82] and better results for the 
secondary endpoints, same as the enzalutamide trial. 
 
Moreover, Abiraterone has proven to prolong progression free survival and time 
to initiation of chemotherapy in patients who have not received chemotherapy 
so far. In this study, patients with asymptomatic castration resistant prostate 
cancer were randomized either to receive 1000 mg of Abiraterone + 10 mg 
Prednisone daily or Placebo + 10 mg Prednisone [83]. 
 
1.5.3.4 Radium-223 
Radium-223 is a newly developed radioactive medication to treat bone 
metastases caused by different types of cancer. It is injected intravenously and 
is taken up by the bone, since its chemical structure is similar to that of calcium. 
It emits up to 96% alpha radiation, which has a very short range, reaching 
mostly cancer cells and sparing the surrounding tissue. This presents a great 
advantage compared to external radiation which is normally used to treat pain 
from bone metastases, but has limited tissue selectivity, has a high toxicity and 
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causes bone marrow suppression. This advantage can also be seen compared 
to other bone seeking medication such as strontium-89, which emits beta 
radiation which has a wider range than alpha radiation [84]. In phase II studies it 
was demonstrated that radium-223 has a positive effect on bone metastases-
related pain and biomarkers (PSA and bone alkaline phosphatase) [85, 86]. 
Moreover, the ALSYMPCA trial, a phase III double-blind, randomized study 
conducted with 921 CRPC men showed an improved overall survival for the 
radium-223 group compared to the placebo group [87]. Conclusively, it can be 
said that radium-223 can be safely utilized for treating bone metastases in 
CRPC even in combination with the above mentioned therapies, since its 
mechanism of action does not interfere with these other treatments. Currently 
radium-223 combined with docetaxel is being tested on a phase I-II trial [88]. 
 
There are no clear recommendations which therapy is the most appropriate in 
CRPC patients with disease progression after docetaxel therapy. Enzalutamide, 
arbiraterone, cabazitaxel have showed improvement of overall survival in these 
patients, but to date there are no data available from randomized trials 
comparing different therapy sequences. Also, the costs of these new treatments 
are very high which presents an immense challenge for the public health 
system. 
 
1.5.4 Follow-up after treatment of localized prostate cancer 
Even though most patients with localized prostate cancer get treated with a 
curative intention, some will have a disease relapse. The goal of follow-up is to 
identify treatment complications or disease relapse in time to proceed with a 
second-line curative therapy or delay clinical disease progression. For this 
purpose, two important concepts have been developed: biochemical disease 
relapse and clinical disease relapse. For the first one PSA value samples are 
routinely assessed; for the second one, the DRE and a detailed symptom 
history of the patient are indispensable. Imaging diagnostics are not used 
routinely for follow-up of patients treated with a curative intention; generally, 
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imaging techniques should be used for patients with biochemical or 
symptomatic disease recurrence, but only for those for whom the imaging 
results will provide useful information as to how to proceed therapeutically.  
 
The risk for therapy failure and consequentially disease recurrence is highest 
during the first years after therapy. This is why follow up should be conducted 
more thoroughly at the beginning: according to the European Association of 
Urology guidelines, after three, six and twelve months after RP, every six 
months during the following two years, and then yearly. Taking into 
consideration that the patients in our study all underwent RP, a focus will be set 
on follow-up treatment for patients after RP. 
 
1.5.4.1 PSA progression and PSA monitoring 
For patients after RP, PSA progression is defined as at least two consecutive 
PSA measurements > 0,2 ng/mL [89] . It has been suggested though that for 
patients with a higher risk of disease relapse, PSA progression should be 
defined as two measurements >0,4 ng/mL [90] . Six weeks after a successful 
RP, PSA levels are expected to sink until PSA is no longer detectable [91]. The 
persistence of elevated PSA values is considered as a sign of local remaining 
tumorous tissue, or micrometastasis. At this point, the behavior of PSA can also 
bring information as to where the source of PSA might be; in the case of local 
disease recurrence, PSA tends to rise late and slowly, whereas by distant 
metastases, PSA rises rapidly and the PSA doubling time is rather short [92]. 
Biochemical relapse usually precedes clinical relapse, sometimes even for 
years. Although, not all patients with biochemical relapse develop automatically 
a clinical relapse. According to Pound et al., 34% of 1997 evaluated patients 
who had had biochemical recurrence eventually developed clinical recurrence 
[93]. Boorjian et al. presented similar results after analyzing the data of 2400 
patients, from which only 23% proceeded to develop a clinical recurrence after 
initial biochemical recurrence [94]. 
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1.5.4.2 Clinical recurrence and monitoring 
Besides PSA monitoring, regular DRE remains the most important examination 
in the follow up of patients after prostatectomy. A recurrence without PSA 
increase is most probable in patients with low differentiated tumors [95]. If a 
local recurrence is expected, transrectal sonography may be indicated as 
further examination.  
 
When speaking of tumor recurrence, there is a difference between a local and 
systemic recurrence. As mentioned above, a PSA increase early after 
prostatectomy indicates systemic disease relapse. Moreover, patients with low 
differentiated tumors (e.g. Gleason 9 or 10) or nodal involvement have an 
increased risk of systemic recurrence [96]. Clinical symptoms such as 
obstructive voiding symptoms or hematuria are present only in a low proportion 
of patients with local relapse. In case of distant recurrence and bone 
metastases, pathologic fractures or bone pain often present the first symptoms 
of metastatic bone disease. If systemic recurrence is suspected, bone scan and 
whole body computed tomography are indicated. A study showed that a bone 
scan of a patient with PSA relapse has a probability of <5% to show 
pathological results related to tumor relapse if the PSA level is lower than 7 
ng/ml [97]. Choline-PET-CT is indicated in patients who are candidates for local 
salvage therapy to visualize the local situation and rule out systemic recurrence. 
However, in patients with a PSA <4.0 ng/ml, the value of Choline-PET-CT is 
considered critically [98].  
 
1.5.5 Treatment of biochemical recurrence 
The rate of biochemical recurrence among men after RP varies depending on 
the different pathological risk factors (surgical margins, postoperative lymph 
node status, Gleason score, postoperative PSA levels and behavior) [99]. The 
numbers slightly differ: Han et al. analyzed data of men who submitted 
themselves to RP and found that the biochemical recurrence free survival was 
approx. of 84% after 5, 74% after 10 and 66% after 15 years [100]. Porter and 
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his group showed in a similar analysis a biochemical recurrence free survival of 
85%, 61% and 55% at 5, 15 and 25 years past RP time [101]. There are three 
options for the management of a patient with PSA relapse: radiation, ADT and a 
“wait and see” approach (parting from the already discussed fact that not every 
PSA-relapse evolves into a clinical relapse). Currently, there are no studies 
comparing these therapies with regards to overall survival after biochemical 
relapse. Mehta and his group examined data of 303 patients who had had a RP 
and biochemical relapse and stated that 43% of these men continued to be 
treated with radiation and 57% with hormone therapy [102]. According to their 
study, a high PSA level and seminal vesicle invasion were criteria common to 
those men who received ADT.  
 
Radiation after surgical therapy can be given to the patient as adjuvant 
treatment (radiation three months postoperatively disregarding PSA levels) or 
as salvage radiation therapy (after a confirmed biochemical relapse). Radiation 
therapy for biochemical recurrence seems to be most effective, when performed 
at a time when the PSA level is <0,5 ng/ml [103, 104]. If done correctly, salvage 
radiation therapy can give patients up to 80% chances of living the next 5 years 
without disease progression [105]. A retrospective study showed that patients 
who had undergone salvage radiotherapy had a three times higher prostate 
cancer related survival compared to men who did not receive such treatment 
[106]. There are no data suggesting that adjuvant or salvage radiation have a 
benefit for survival [107]. Therefore, the decision to follow one or the other must 
be made between physician and patient. One reason that could lead physicians 
to wait for PSA relapse to proceed with radiation is the side effects of radiation. 
Though, the incontinence rate amongst men after second line radiation does not 
differ significantly from men without radiation [108]. 
 
The effect of ADT after disease relapse has already been discussed previously 
(see chapter 1.5.2.1). Moul et al. showed with a retrospective analysis that the 
time when ADT is started (after biochemical relapse or after relapse plus 
metastasis) did not make any difference in the time to distant metastasis 
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development [109], nor did it have a positive impact on PC related mortality. 
The “watch and see” strategy is most likely to be successful for men who 
present a PSA doubling time >12 months [94], but the indication is not stated 
easily. It is also a possibility for men with a life expectancy lower than 10 years 
or those who do not want to submit themselves to salvage radiation. 
 
2. Immune therapy for prostate cancer 
 
2.1 Cancer immunology 
2.1.1 The role of the immune system in tumor development  
The immune system plays as a crucial role as a guard in tumorigenesis. The 
theory of “immunoediting” states that the process from the transformation of 
regular cells into tumorous cells and their further development into a tumor 
happens in three phases: elimination, equilibrium, and escape. The first phase 
called “elimination” or “immunosurveillance" is described as the immune 
system’s ability to differentiate between the body’s own and foreign tissue and 
also of recognizing the host's own cells that degenerate (through chemical, 
genetic, viral alterations or spontaneously) and destroying these [110, 111]. 
According to this theory, a properly functioning immune system is able to 
counteract the emersion of tumors by eliminating malignant cells, thus 
protecting the host. The emerging tumorous cells generate a proinflammatory 
response and this leads to tumor elimination. However, if the host’s response is 
not successful in eradicating the malignant cells, they enter an “equilibrium” 
phase. In this phase the cells begin changing their qualities and the ones which 
present most resistance against the unfriendly environment created from the 
host’s immune reaction keep proliferating. If a cell variant succeeds to develop 
immune evading mechanisms, the immune system gets overrun, the balance 
can no longer be held and the tumor becomes clinically apparent (“escape”)  
[112, 113]. 
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The immune system’s response against the emerging tumor can be explained 
using the concept of an "adaptive immune response" [114], which describes the 
following: in the presence of a tumor associated antigen (TAA), immature 
antigen presenting cells (APCs), most importantly dendritic cells (DCs), are 
activated. The antigen is taken up and after a conversion process it is 
expressed on the surface of mature DCs in the form of smaller peptides on their 
MHC I and II molecules. The activated DCs migrate to the lymph nodes where 
the peptides together co-stimulatory molecules (B7 ligands interact with the 
CD28 receptor on T cells) are presented to CD4 + cells and CD8 + cytotoxic T-
lymphocytes. This is a very complex process though, since antigen presentation 
from DCs and recognition from T cells is not enough for them to become active, 
but additional signals are just as important as antigen presentation itself. If T 
cells are activated, CD4 + cells produce cytokines which contribute to full CD8 + 
maturation. These mature CD8 + cells infiltrate the tumor tissue, where the 
same MHC-peptide complex that activated them is expressed and induce a 
lysis [115]. Not only do they lyse tumorous cells on their source, but the 
activated CD8 + cells search the host for remaining cells to eliminate [116]. 
However, when T cell activation occurs inhibitory pathways are also activated. 
Such innate processes play an important role in the decay of immune 
responses after infections for example or preventing autoimmunity, but can 
inhibit or abort the immune response against tumors, letting these proliferate 
and grow [114]. 
 
Unfortunately, tumors possess strategies to escape from the immune system 
and inhibit an immune response [117]. One of the main mechanisms is the 
production and expression of certain molecules which restrict the functions of T 
cells [118]. These molecules are called “immune checkpoints” [119, 120], 
among which are ligands for known receptors which regulate the T-
lymphocytes: the inhibitory programmed death-1 (PD-1) and the cytotoxic T-
lymphocyte associated receptor 4 (CTLA4) [114]. Stimulation of these receptors 
limits T cells. Preclinical studies showed that the blocking of CTLA4-receptor 
enhanced T cells to perform their function properly [121]. One known evasion 
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mechanisms of tumors is that their malignant cells can prevent the maturation 
process of dendritic cells (DC). DCs are the main representatives of the T-cell-
stimulating APCs and they block the secretion of costimulatory molecules 
needed for the activation of T cells. Moreover, the conversion process of the 
TAAs to smaller presentable peptides and the expression of MHC molecules on 
the surface of APCs can be down-regulated or blocked, preventing T-cell 
activation [122, 123]. Another feature that some tumors possess in order to 
escape the host’s immune protective strategies is the secretion of 
immunomodulatory factors such as GM-CSF, TNF, TGF-ß1 and vascular 
endothelial growth factor (VEGF). These factors are of great importance in the 
conversion of peripheral myeloid cells to so-called MDSCs (myeloid-derived 
suppressor cells and tumor-associated macrophages) [124], which play a 
crucial role in creating favorable conditions for the growth of the tumor by 
creating oxidative stress and producing nitric oxide, among others [125, 126]. 
MDSCs appear often in patients’ blood who have metastatic bladder cancer or 
renal cell carcinoma (RCC) [127] and there appears to be a correlation between 
the MDSC rate in blood and the patient’s disease stage.  
 
2.1.2 The theory behind cancer vaccines 
The goal of cancer vaccines is the stimulation of the cellular part of the human 
immune system, focusing on B- and T-cells, thus giving the body a chance to 
bring back to balance the tumor-immune system interaction. To generate a 
lymphocyte response, these cells have to be accurately activated by DCs 
through antigen presentation. DCs have to be stimulated first though, and that is 
the goal of cancer vaccines. For this stimulation to be effective, cancer vaccines 
until present time have been made out of two components: an adjuvant and the 
target peptide or protein that should be later presented to activate T and B 
lymphocytes. Adjuvants, also known as pathogen-associated molecular 
patterns [128], are substances that are intended to encourage DC activation, 
enlarging the vaccines immunogenicity. The peptide component is delivered to 
the host in different forms, but is customized to the tumor entity, to match the 
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same molecule expected to be found overly expressed in the tumorous cells. A 
lot of effort has been put on the identification of TAAs as a target for T-cells and 
on the characterization of the from these TAAs derived peptides that act as 
epitopes on HLA molecule presentation by APCs [129]. Most TAAs are proteins 
which are not specific to tumor tissue but already exist on regular prostate cells. 
On the tumor though, they are overly expressed or their structure is altered due 
to gene-mutation of the malign cells. In some cases completely new proteins 
result from the aberrations in tumorous cells. Some of these structures are not 
only expressed in prostate cancer, but in other tumors as well.  
 
2.1.3 Immune therapy in prostate cancer 
Up until now melanoma and renal cell carcinoma have been the key targets of 
immunotherapeutic approaches, given that spontaneous regressions of both of 
these tumors [130] have been observed and they both present a dense CD8+ 
cell infiltration in tumor tissue [131]. Even though for a long time prostate cancer 
was not considered an immunological tumor  as were both the above mentioned 
cancers, there are many reasons to think otherwise and several arguments for 
considering immune therapy as a possibility for treating this disease. Patients 
with prostate cancer spontaneously develop antibodies against tumor antigens. 
This leads to the conclusion that this type of cancer does possess more 
immunogenicity than was previously attributed to it [132]. Many different TAAs 
and prostate specific antigens which can be used as targets have been 
identified, for example PSA (prostate specific antigen), PCSA (prostate stem 
cell antigen), PSMA (prostate specific membrane antigen), TRP-P8 (transient 
receptor potential p8), survivin and prostein [129, 133, 134].  Also, prostate 
cancer is a slow growing tumor which is favorable to the immune system 
because it has more time to generate a directed antitumor response. 
Furthermore, there is enough data proving that immune therapy has most 
success when combined with other therapies which reduce the tolerance of the 
immune system against the tumor, for example radiation and ablative hormone 
therapy [117, 135]. 
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Because the prostate is a nonvital organ, immunotherapy has the other great 
advantage, that the potential target molecules on the tumor cells are not only 
tumor specific. In the case of a radical prostatectomy, since the goal is to 
remove the organ and possible metastatic cells in lymph nodes, if a patient has 
a biochemical disease relapse it is assumed that there are remaining tumorous 
cells. Having removed the healthy prostate cells the mutated cancer ones can 
easily be targeted or marked not only using the tumor proteins, but using the 
prostate specific tissue molecules as well.  
 
2.1.4 Cancer vaccines as treatment for prostate cancer 
There have been several immunological approaches for the development of a 
new prostate cancer therapy. The most notable advances have focused on 
ways to deliver tumor-associated-antigens to patients so as to stimulate a T-cell 
response. These include antigens with viral vectors, DNA-based and RNA-
based vaccines, peptide vaccines among others.  
 
One of the main agents of this group and the only FDA (Food and Drug 
administration) approved drug in the field is Sipuleucel-T (commercial name 
Provenge). It is an autologous (and therefor personalized) APC-based Vaccine 
which uses ex vivo antigen presentation for stimulating an immune response in 
vivo. The cells are gained from the patient’s blood by leukapheresis. These 
spend 36-44 hours in a sterile culture with the protein PA2024, a fusion protein 
from PAP and GM-CSF [136]. The decision of using PAP was based on the fact 
that xenogeneic forms of PAP have been proven to induce prostate-specific 
immunity on rats and humans [137].  GM-CSF is thought to enhance dendritic 
cells maturation. After the in-vitro activation of the now antigen loaded cells, 
these are reinfused to the patient. The goal is that the treated APCs target PAP-
carrying tumorous cells, thus inducing tumor inhibition. The therapy consists in 
three series of leukapheresis-infusion treatments, each round two weeks apart. 
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Three randomized controlled studies led to the approval of sipuleucel-T. In all 
three trials patients in the placebo group received an infusion of autologous 
cells cultured without PA2024 with the possibility of being vaccinated with 
sipuleucel-T in the case of disease progression. The first phase III trial included 
127 men with asymptomatic metastatic CRPC. The distribution into the placebo 
and sipuleucel-T group was effected randomly at a ratio from 2:1 (82 patients 
received sipuleucel-T and 45 the placebo). The primary endpoint of the trial was 
not met, since there was no significant difference in the time to disease 
progression (TTP). However, the overall survival (OS) showed an improvement 
for sipuleucel-T of 4 months over placebo [138]. The second trial was similar to 
the first one, but did not demonstrate a benefit for sipuleucel-T, neither on the 
TTP nor on the OS. The third trial (IMPACT trial, Immunotherapy for Prostate 
Adenocarcinoma Treatment) enrolled 512 asymptomatic CRPC patients, also 
organized in a placebo and sipulecuel-t group on a ratio of 2:1. The primary end 
point was the overall survival which was significantly improved in the sipulecuel-
T group (sipuleucel-T 25.8 months vs. 21.7 for placebo), the TTP showed no 
significant improvement [139].  Patients in the placebo arm who showed 
disease progression could be vaccinated with sipuleucel-T after a certain 
amount of time, which happened in 109 of 171 cases. A follow-up therapy with 
Docetaxel was allowed. This happened in 190 out of 341 cases of sipuleucel-T 
treated patients and in 86 of 171 placebo treated patients. The overall survival 
improvement in the sipuleucel-t group proved to be independent from the 
docetaxel treatment [139]. 
 
Another approach for treating prostate cancer is using tumor cells as 
immunological vectors. GVAX consists of allogeneic prostate tumor cell lines 
(LNCaP and PC3) cultured from numerous individuals (differing in MHC tissue 
type). These cells are treated with radiation in order to prevent further 
proliferation and are genetically altered through viral transfer for secretion of 
GM-CSF [140]. Two Phase II studies conducted with CRPC patients showed 
positive effects: one showed an OS of 26.2 months and the other one an OS 
between  20.0 and 29.1 months [141, 142]. This lead to the VITAL-1 and VITAL-
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2 randomized phase III studies. VITAL-1 included 626 asymptomatic CRPC 
chemotherapy-naive patients, randomly divided into two groups, one being 
treated with GVAX and the other one with prednisone/docetaxel. The interim 
analysis showed the primary endpoint of the study (prolonged OS) was not 
likely to be achieved, and the study was interrupted. The final analysis after 279 
of the 626 study-patients had died displayed an overall survival of 20.7 for the 
GVAX group vs 21.7 months for the prednisone/docetaxel group. 
 
A further approach is PROSTVAC-VF. This vaccine is a mixture of recombinant 
fowlpox and vaccinia viruses encoding transgenes for PSA and three T-cell co-
stimulatory substances (intercellular adhesion molecule, lymphocyte function-
associated antigen 3 and B7-1, all three substances together are also known as 
TRICOM) which help to amplify the immune response [143]. A phase II, double-
blind randomized study for PROSTVAC-VF was conducted with 125 CRPC 
men; the placebo group received an empty vector, the treatment group received 
PROSTVAC-VF. This trial did not meet its primary endpoint, a prolonged 
progression- free survival but an analysis of the same study done 3 years 
afterwards showed an improvement in the OS for the PROSTVAC-VF group 
(median OS 24,5 months) versus the placebo group (16,0 months) [144]. A 
Phase III trial of PROSTVAC-VF is now being conducted in men with 
asymptomatic or minimally symptomatic CRPC[145]. 
 
Another type of immunotherapy for prostate cancer is a DNA based vaccine 
encoding tumor antigens. A DNA plasmid is processed by the DCs and then 
expressed on their surface for further T cell activation. A phase I/II study was 
done using DNA plasmids encoding PAP and pro-inflammatory agents which 
recruit and activate DCs (TLR agonists and GM-CSF). The treatment was 
applied to men with a biochemically recurrent non-metastatic disease [146]. The 
results showed an antibody and T cell response against PAP [147], and a 
deceleration in PSA rate rise could also be observed. 
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Similar to DNA vaccines there has also been an attempt to stimulate an immune 
response with RNA. CV9103 is a vaccine that consists of full length mRNA 
encoding PSCA, PSMA, PSA and STEAP1 (six transmembrane epithelial 
antigen of the prostate 1) [148]. A phase I/IIa study included 38 patients with 
CRPC with and without metastasis; the patients were injected with CV9103 
subcutaneously and monitored closely. The vaccine was generally well 
tolerated. Results reported a response against several antigens in 58% of the 
patients and 74% showed a T-cell response against minimum one of the 
antigens. In isolated cases, patients showed a stabilization of their PSA levels. 
Noguchi et al. [149] performed a phase II randomized trial using a personalized 
peptide vaccination (PPV) in patients with CRPC. The trial included 57 patients, 
28 of which received PPV combined with low dose estramustine phosphate 
(EMP). 27 patients in the control group received EMP therapy only. The patients 
in the PPV + EMP group were previously vaccinated with a mixture of up to 26 
different peptides derived from different prostate cancer antigens. The immune 
response to this pre-vaccination was measured by IgG antibodies against the 
received peptides. During the actual vaccination therapy, the patients in the 
PPV arm only received a combination of up to 4 peptides, chosen carefully 
according to the strongest immune responses showed during pre-vaccination 
assessment. After a first round of treatment, patients were able to change 
groups in case of disease progression. The primary endpoint of the study was 
progression-free survival assessed by changes in PSA. The study showed an 
improvement in PFS for the PPV plus EMP group compared to the control 
group (median PFS was 8.5 vs 2.8 months, p=0.0012). Also a prolonged overall 
survival was observed for the PPV + EMP group compared to the EMP only 
group (p=0.03) [149]. 
The aim of this study was to assess the clinical outcome of patients who 
underwent multipeptide vaccination treatment and compare their disease 
development with patients who did not receive immune therapy. Multipeptide 
vaccination therapy stimulates the host’s immune system to target and destroy 
prostate cancer cells. The patients who received this treatment should present a 
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longer time to progression (longer time to subsequent cancer specific therapy, 
time to hormone therapy and time to clinical recurrence) and improvement in 
overall survival (OS) compared to patients who did not receive such vaccination 
treatment. 
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Materials and methods 
 
1. Study approval 
The study was approved by the local ethics committee of the medical faculty of 
the University of Tuebingen (358/2014BO2). 
 
2. Patient collective 
The patients included in this study all participated in a clinical trial conducted at 
the University hospital of Tuebingen between 2004 and 2014. The recruitment 
of patients took part between 2004 and 2009. 
All patients were diagnosed with prostate cancer and submitted themselves to a 
radical prostatectomy (performed both at the University Hospital in Tuebingen 
or other clinic in Germany). After an initial postoperative PSA value decrease, 
the patients showed a biochemical PSA relapse. This was defined by the 
increase of two consecutive PSA values from the nadir after RP or radiation, 
evaluated by two measurements at least 14 days apart.  
The collective of the present study consists of two groups: 36 patients who were 
included into the clinical trial and 65 patients that had a screening failure due to 
reasons stated below, 101 in total. For the clinical trial, 154 patients were 
screened in total (see study criteria below). HLA Status was determined for 
each of these patients. HLA-A2 status was the main inclusion criterion. Of the 
154 patients screened, 55 patients were HLA A2 positive. Of these 55 patients 
36 were included into the vaccination trial. The 19 patients who were HLA A2 
positive were not included in the clinical trial because they rejected it, or they 
did not meet the inclusion criteria. Of these 19 HLA A2 positive patients, 16 
were included in the control group. From the 99 HLA A2 negative patients, 49 
were included into the study. The remaining 50 patients that were screened but 
not included in the clinical trial were not included in this study as they could not 
be contacted or they rejected the proposal of being part of this study (see 
Figure 1). 
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Figure 1: Study Cohort. Patients in green and yellow boxes were included in the present study. 
The patients in the green boxes served as control group whereas the patients in the yellow box 
formed the treatment group. * screening failure due to other reasons than HLA status. 
 
3. Vaccination trial 
The criteria for inclusion in the vaccination study were the following: 
 Positive HLA A2 status  
 Age between 45 and 80 
 Biochemical disease defined by the increase of two consecutive PSA 
values from the nadir after RP or radiation, evaluated by two 
measurements at least 14 days apart.  
 No therapy for treating biochemical disease recurrence (adjuvant 
therapies were allowed only in the case that they were performed before 
PSA recurrence). 
HLA Screening for 
clinical trial:  
154 patients 
HLA positive:  
55 patients 
Inclusion in 
clinical trial / 
Vaccination: 
36 patients 
Screening 
failure*: 
19 patients 
HLA negative: 
99 patients 
49 patients 
16 patients 
 41 
 
 No local recurrence, nodal or distant metastases assessed by CT, MRI 
or bone scan 
 No immune modulatory therapies, no corticoid therapy 
 No simultaneous radiation, hormone deprivation therapy or 
chemotherapy 
 No concomitant tumor, epileptic or pulmonary disease 
 Eastern Cooperative Oncology Group performance status of 0 or 1 [150]. 
Exclusion criteria for the vaccination study: 
 Karnofsky Index <70 
 No consent from the patient 
 Presence of a second tumorous disease  
 Known obstructive lung disease and a predisposition for allergies  
 Use of medication that alters or has an effect on the immune system  
 Simultaneous radiation treatment 
 Seizure disorder  
 
3.1 Clinical trial procedures 
The vaccine consisted of 14 different, synthetic peptides, all of them HLA I and 
II binding molecules derived from prostate tissue specific antigens or prostate 
cancer associated antigens, aside from one derived from an influenza virus, 
which was thought as a marker peptide for memory T-cell activation [151]. 
These were selected to target a broad range of CD4+ and CD8+ T-cells, trying 
to prevent tumor escape. The peptide mixture in a Montanide ISA emulsion was 
injected subcutaneously to the patients, along to either one of four different 
adjuvants or no adjuvant at all. Between the possible adjuvants were GM-CSF, 
Imiquimod, a mucin-1-mRNA/protamine complex and hyperthermia which were 
thought to boost immune stimulation. The patients received the injections on the 
abdominal wall, always on the same area, on days 0, 7, 14, 28, 42 and 56. After 
each vaccination patients were thoroughly monitored and not discharged until 
adverse effects or toxicity were discarded. PSA was monitored at each 
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vaccination. After Day 56, if no PSA progression or clinical disease progress 
were observed, patients continued to be vaccinated every 4 weeks until day 
number 420 (approximately 18 months). After concluding with the vaccination 
program, patients were further monitored by their urologist or family doctor. 
 
4. Assessment of follow-up 
For the present study, follow-up of the 101 patients included was obtained 
either by in-house follow-up or by contacting the patient. To determine the latest 
survival status, cause of death, date and type of clinical progression and PSA 
measurements, the patients were contacted and/or the hospital’s records were 
reviewed. Clinical endpoints were registered based on the latest available 
information before cut-off-date July 1st 2012. Clinical recurrence was defined as 
any comeback of the disease: local recurrence, nodal disease, bone or visceral 
metastasis. Distant metastasis was defined as bone or visceral metastasis. The 
term subsequent therapy includes all prostate cancer specific therapies which 
the patient received after the screening for the study or after the vaccination 
trial. Since the majority of the patients proceeded with their follow up treatment 
and monitoring outside of the hospital, the patients had to be contacted. Each 
man received an explanatory letter (see Figure 2) giving them the possibility of 
participating (clearly stated that it was voluntary to be included in the study). All 
patients were then contacted by phone and after verbally agreeing to taking part 
in the study, they were asked several questions about the course of their 
disease (see Figure 3). Patients who could not answer these questions by 
themselves allowed us to contact their family physician or urologist to get the 
information. An additional follow-up took place in March 2015 to update 
patients’ data with regard to their subsequent therapy. The same steps as 
before were followed to contact the patients and collect the information. 
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Figure 2. Letter sent to patients before initiating survey for the study. 
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Figure 3. Telephone protocol for patient follow-up. 
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Gathered data:  
Preoperative: 
 Date of birth/age 
 Preoperative PSA-value 
Postoperative: 
 Date of prostatectomy 
 pTNM-Stadium 
 Resection margins 
 Gleason Score 
 Date of screening for the study 
 HLA-Status 
 Start and end dates of vaccination study (when applicable) 
After study/after screening for the study: 
 PSA value trend 
 Type of PC-related therapy prior to screening 
 Type of PC-related therapy after screening 
 Presence and date of local disease relapse (assessed by CT-Scan, bone 
scan or MRI) 
 Presence and date of nodal and distant metastases (assessed by CT-
scan, bone scan or MRI) 
 Survival status/cause of death 
 
5. Statistical analysis 
Statistical analysis of data was performed using SAS JMP 10.0 (Cary, USA) 
and IBM SPSS 22 (Armonk, NY, USA).. For estimation of time to recurrence, 
time to metastasis, time to next therapy and time to androgen deprivation 
therapy, Kaplan Meier curves were used. For analysis of Kaplan-Meier curves, 
Log Rank tests were performed. In case of non-constant event rates, indicated 
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by a crossover of the curves in Kaplan-Meier estimates, Wilcoxon test was 
performed. Differences in clinicopathological parameters between the 
vaccinated and non-vaccinated group were assessed by Wilcoxon-Mann-
Whitney tests, Wilcoxon-Kruskal-Wallis tests and Cochrane-Armitage tests for 
trend. A p value of less than 0.05 was considered statistically significant.  
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Results 
 
1.  Description of study cohort 
 
1.1. General clinicopathological data. 
 
In total, 101 male were included. The median age at time of randomization was 
65 years (Range 45-81).  
Tumor stage from prostatectomy samples was available in 85 patients. Of 
these, 42 (49.4%) had a locally advanced tumor (pT≥3). Nodal status from time 
of prostatectomy was available in 85 patients. Of these, 9 (10.6%) had nodal 
positive disease.  
Preoperative PSA levels were available in 72 patients. The median preoperative 
PSA was 9.55 ng/ml (1.5-34.6).  
Gleason Patterns and Surgical resection margin status are shown in Table 3.  
 
1.2. HLA Status and vaccination group 
 
Of 101 patients, 52 were HLA A2 positive (51.5%). Of the HLA A2 positive 
patients, 36 (69.2%) were treated with vaccination. There were no differences in 
clinicopathological parameters between vaccinated and non-vaccinated patients 
(see Table 3). 
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Table 3. Description of study cohort. 
 
Total 
(N=101) 
Vaccinated = 1 
(N=36) 
Non-vaccinated = 0 
(N=65) 
p= 
Age 
Median= 65 
Mean= 65.2 
[45-81] 
(N=101) 
Median = 65 
Mean= 64.9 
[52-81] 
Median = 66 
Mean= 65.3 
[45-76] 
0.67 
HLA A2 +/ 
total 
52/101 
(51.4%) 
36/36 
(100%) 
16/65 
(24.6%) 
< 0.0001 
pT (TNM-
Stadium) 
2a= 5 
2b= 11 
2c= 27 
3a=18 
3b= 21 
4= 3 
(N=85) 
2= 1 
2a= 2 
2b= 7 
2c= 11 
3a=4 
3b= 10 
4= 1 
(N=36) 
2a= 3 
2b= 4 
2c= 16 
3a=14 
3b= 11 
4= 2 
(N=50) 
0.50 
(Cochrane 
Trendtest) 
Fraction of 
advanced 
stage tumors 
pT≥3 
42 (49.4%) 
(N=85) 
15 (42.8%) 
(N=35) 
27 (54.0%) 
N=50 
0.31 
N positive 
(TNM-Stage) 
9 (10.6%) 
(N=85) 
2 (6.3%) 
(N=32) 
7 (13.2%) 
(N=53) 
0.31 
M positive 
(TNM-Stage) 
0 
(N=75) 
0 0 n.a. 
R1 resection 
24 (34.8%) 
(N=69) 
10 (37.0%) 
(N=27) 
14 (33.3%) 
(N=42) 
0.75 
Median 
Gleason-
Score 
7 
[5-9] 
(N= 71) 
7 
[5-9] 
(N=29) 
7 
[5-9] 
(N=42) 
0.10 
Preoperative 
PSA-value 
Median: 9.55 
[1.5-34.6] 
(N=72) 
Median: 8.85 
[3.6-34.6] 
(N=32) 
Median: 9.7 
[1.5-26.8] 
(N=40) 
0.68 
Fraction of 
patients with 
therapy 
between RP 
and 
screening 
37/101 (36.6%) 13 (36.1%) 24 (36.9%) 0.94 
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1.3 Treatment after prostatectomy and before vaccination/screening 
 
Of 101 patients, 37 patients received a cancer-specific therapy between 
prostatectomy and inclusion into the study.  
Table 4. Number of patients who received therapy after prostatectomy and 
before vaccination/screening 
 Therapy 
Radiation ADT Chemotherapy 
Radiation 
+ ADT 
Radiation + 
Chemotherapy 
Patients 
(whole 
cohort) 
16 8 1 11 1 
Vaccinated 4 4 0 4 1 
Non-
vaccinated 
12 4 1 7 0 
 
As a therapy before vaccination might have impacted the results of the study, 
subgroup analyses were performed for those patients, who did not receive any 
treatment between prostatectomy and inclusion into the study. 
 
1.4 Course of disease  
 
The mean follow up was 61.7 months (median 64 months [range: 31-91])..The 
mean time to clinical recurrence after inclusion in the study was 47.1 months 
(median 55 months [range 1-91]). The mean time to the development of distant 
metastases was 53.4 months (median 60 months [range 2-91]). During the 
follow-up, 13 patients (12.9%) had local recurrence or nodal disease and 21 
patients (20.8%) a distant recurrence (distant metastasis). The proportion of 
patients who had no clinical recurrence after 2 and 5 years after screening was 
83.0% and 70.7% (see figure 4). The proportion of patients without distant 
metastases after 2 and 5 years after screening was 89.0% and 82.6% (see 
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figure 5). Recurrence patterns in vaccinated and non-vaccinated patients are 
shown in table 5.  
 
Figure 4: Proportion of patients without clinical recurrence. 
Vaccinated and non-vaccinated patients combined. 
 
 
Figure 5: Proportion of patients without distant metastases.  
Vaccinated and non-vaccinated patients combined. 
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Table 5. Local and distant disease recurrence 
 Recurrence 
Local/ 
regional 
recurrence  
Distant 
metastasis 
Patients 
(whole 
cohort) 
13 21 
Vaccinated 3 5 
Non-
vaccinated 
10 16 
 
1.5 Treatment after screening 
 
The mean time to next therapy after inclusion in the study was 16.4 months 
(median 12 months [range 0-86]). The mean time to hormone therapy was 26.1 
months (median 31 months [0-91]). During the follow-up, 83 patients received 
treatment after screening. 45 (44.6%) received radiotherapy, 34 (33.7%) 
patients had antihormonal treatments, 2 patients (2.0%) chemotherapy, 1 
patient received both antihormonal therapy and radiation (1.0%) and 1 patient 
received surgery (1.0%). The rate of patients without subsequent therapy after 
screening after 2 and 5 years was 36.6% and 17.6% (see figure 6). The rate of 
patients without subsequent hormone therapy after screening after 2 and 5 
years was 58.4% and 39.5% (see figure 7). Subsequent treatments in 
vaccinated and non-vaccinated patients are shown in table 6. 
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Figure 6: Proportion of patients without subsequent therapy.  
Vaccinated and non-vaccinated patients combined. 
 
 
 
Figure 7: Proportion of patients without subsequent hormone therapy.  
Vaccinated and non-vaccinated patients combined. 
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Table 6. Therapies received by the patients after vaccination/screening. 
 Therapy 
Radiation ADT Chemotherapy 
Radiation + 
ADT 
Surgery 
Patients 
(whole 
cohort) 
45 34 2 1 1 
Vaccinated 13 11 1 2 1 
Non-
vaccinated 
30 23 1 1 0 
 
 
1.6 Overall survival and cancer specific survival 
 
During the follow-up, 5 patients (5.0%) became deceased: 2 (5.5%) from the 
vaccinated group, and 3 (4.6%) from the non-vaccinated group. All deaths were 
caused by prostate cancer. After 2 and 5 years, the proportion of patients 
surviving was 100.0% (n=101)  and 97.3% (n=98). 
   
 
Figure 8: Proportion of patients surviving.  
Vaccinated and non-vaccinated patients combined. 
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2. Outcome comparison between vaccinated and non-vaccinated patients 
 
2.1 Recurrence free survival: any clinical recurrence (local, nodal or distant 
metastasis) 
2.1.1 Time to clinical recurrence from screening (whole cohort) 
The proportion of patients without clinical recurrence after 2 and 5 years after 
screening for the study was 91.4% and 82.1% for the vaccinated group and 
78.5% and 64.3% for the non-vaccinated group (p=0.06). 
 
 
 
Figure 9: Proportion of patients without clinical recurrence after screening.  
Comparing vaccinated group vs. non-vaccinated group. Whole cohort, n=101 (p=0.06 log-rank 
test) 
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2.1.2 Time to clinical recurrence from screening (patients without cancer-related 
therapy between prostatectomy and screening) 
In the subgroup of patients without any therapy between prostatectomy and 
screening the proportion of patients without clinical recurrence 2 and 5 years 
after screening for the study was 91.3% and 81.2% in the group of vaccinated 
patients and 73.8% and 58.3% in the non-vaccinated patients group (p=0.05). 
 
 
 
 
Figure 10: Proportion of patients without clinical recurrence after screening.  
Comparing vaccinated group vs. non-vaccinated group. Included are only patients who did not 
become any prostate cancer specific therapy between prostatectomy and screening, n=64 
(p=0.05 log-rank-test) 
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2.2 Recurrence free survival: distant metastasis 
2.2.1 Time to development of distant metastasis (whole cohort) 
The proportion of patients without distant metastases after 2 and 5 years after 
screening for the study was 97.1% and 87.4% for the vaccinated group and 
84.6% and 80.0% for the non-vaccinated group (p=0.21). 
 
 
 
Figure 11: Proportion of patients without distant metastases after screening.  
Comparing vaccinated group vs. non-vaccinated group. Whole cohort, n=101 (p=0.21 log-rank 
test) 
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2.2.2 Time to development of distant metastasis (patients without cancer-
related therapy between prostatectomy and screening) 
In the subgroup of patients without any therapy between prostatectomy and 
screening the proportion of patients without distant metastases 2 and 5 years 
after screening for the study was 95.7% and 89.7% in the group of vaccinated 
patients and 83.3% and 76.2% in the non-vaccinated patients group (p=0.19). 
 
 
 
Figure 12: Proportion of patients without distant metastases after screening.  
Included are only patients who did not become any prostate cancer specific therapy between 
prostatectomy and screening, n=64 (p=0.19 log-rank test) 
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2.3 Overall and cancer specific survival (whole cohort) 
 
The proportion of patients surviving at the end of follow up was 97.3% for the 
vaccinated group and 95.4% for the non-vaccinated group. 
The proportion of patients surviving after 2 and 5 years after screening for the 
study was 100% for both the vaccinated group and the non-vaccinated group 
after 2 years, and 100% and 93.3% after 5 years (p=0.89). 
 
 
 
Figure 13: Overall Survival. Comparing vaccinated group vs. non-vaccinated group. 
 Whole cohort n=101 (p=0.98 log-rank test) 
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2.4 Time to subsequent prostate cancer-specific therapy 
2.4.1 Time to subsequent therapy after screening (whole cohort) 
The proportion of patients without cancer-specific treatment 2 and 5 years after 
screening for the study was 41.7% and 21.9% in the group of vaccinated 
patients and 33.9% and 15.2% in the non-vaccinated patients group (log-rank 
test p=0.09. Wilcoxon test p= 0.01). 
 
 
 
 
Figure 14: Proportion of patients without subsequent therapy after screening. Comparing 
vaccinated group vs. non-vaccinated group. Whole cohort, n=101 (p=0.09 log-rank test. p= 0.01 
Wilcoxon test) 
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2.4.2 Time to subsequent prostate cancer specific therapy after screening 
(patients without cancer-related therapy between prostatectomy and screening) 
In the subgroup of patients without any prostate cancer specific therapy 
between prostatectomy and screening the proportion of patients without cancer-
specific treatment 2 and 5 years after screening for the study was 43.5% and 
26.1% in the group of vaccinated patients and 33.3% and 11.3% in the non-
vaccinated patients group (p=0.05). 
 
 
 
Figure 15: Proportion of patients without subsequent therapy after screening.  
Comparing vaccinated group vs. non-vaccinated group. Included are only patients who did not 
become any prostate cancer specific therapy between prostatectomy and screening, n=64 
(p=0.05 log-rank test)  
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2.4.3 Time to subsequent therapy after screening (whole cohort). Update 
31.03.2015. 
The mean time to subsequent therapy after screening was 26.53 months for the 
whole cohort, 29.75 months for the vaccinated patients and 24,75 months for 
the non-vaccinated patients (Breslow p=0.046). 
 
Figure 16: Proportion of patients without subsequent therapy after screening. Cut-off date 
31.03.2015. Comparing vaccinated group vs. non-vaccinated group. Whole cohort n=101 
(p=0.046 Breslow; log-rank test p=0.639). 
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2.4.4 Time to subsequent prostate cancer specific therapy from screening for 
non-vaccinated group and from last-vaccination for vaccinated group (patients 
without cancer-related therapy between prostatectomy and screening) 
For the patients who did not receive any prostate cancer specific therapy 
between radical prostatectomy and screening, the data reads as follows: the 
proportion of patients without subsequent therapy after 2 and 5 years after last 
vaccination was both 30.4% and 25.4% for the vaccinated group. For the non-
vaccinated group, as seen above, the proportion of patients without subsequent 
therapy after 2 and 5 years after screening for the study was 33.3% and 11.3%  
(log-rank test p=0.72. Wilcoxon test p=0.15). 
 
 
Figure 17: Proportion of patients without subsequent therapy. Comparing vaccinated vs. 
non-vaccinated group. Included are only the patients who did not receive any prostate cancer-
specific treatment between prostatectomy and screening, n=64. Follow-up time starts for the 
vaccinated group after last vaccination, for the non-vaccinated group after screening (p=0.72 
log-rank test, p=0.15 Wilcoxon test) 
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2.5 Time to subsequent hormone deprivation therapy 
2.5.1 Time to androgen deprivation therapy from screening (whole cohort) 
The proportion of patients without androgen deprivation therapy 2 and 5 years 
after screening for the study was 63.9% and 38.9% in the group of vaccinated 
patients and 55.4% and 39.7% in the non-vaccinated patients group (Log-Rank 
p=0.66. Wilcoxon test p=0.42). 
 
 
 
Figure 18: Proportion of patients without androgen deprivation therapy after screening. 
Comparing vaccinated vs. non-vaccinated group. Whole cohort, n=101 (p=0.66 log-rank test, 
p=0.42 Wilcoxon test) 
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2.5.2 Time to hormone deprivation therapy from screening (patients without 
cancer-related therapy between prostatectomy and screening) 
In the subgroup of patients without any therapy between prostatectomy and 
screening the proportion of patients without hormone deprivation therapy 2 and 
5 years after screening for the study was 78.3% and 53.8% in the group of 
vaccinated patients and 64.3% and 48.1% in the non-vaccinated patients group 
(p=0.46). 
 
 
Figure 19: Proportion of patients without androgen deprivation therapy after screening. 
Comparing vaccinated vs. non-vaccinated group. Included are only patients who did not 
become any prostate cancer specific therapy between prostatectomy and screening, n=64 
(p=0.46 log-rank test) 
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2.5.3 Time to subsequent hormone deprivation therapy from screening (whole 
cohort). Update 31.03.2015. 
The mean time to androgen deprivation therapy was 45.50 months for the 
whole cohort, 43.49 months for the vaccinated patients and 46,57 months for 
the non-vaccinated patients (Mann-Whithney-U-test p=0.91). 
 
Figure 20: Proportion of patients without androgen deprivation therapy after screening. 
Cut-off date 31.03.2015. Comparing vaccinated vs. non-vaccinated group. Whole cohort, n=101 
(Breslow test p=0.049; log-rank test p=0.239). 
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Discussion 
 
Prostate cancer is the most common malignancy in men [115]. In case of a 
localized disease, radical prostatectomy and radiotherapy are available as 
treatment options with a curative intent. The outcome of patients with 
prostatectomy mainly depends on clinicopathological risk parameters such as 
T-stage, Gleason-Score, PSA value and surgical resection margin status [93]. 
Mainly in the group of patients with high risk features, a significant proportion 
experiences biochemical disease relapse. Not all of the patients with 
biochemical relapse will develop clinical disease recurrence or metastases. 
However, the rise of the serum PSA after prostatectomy is considered as an 
event often preceding recurrence and dissemination of tumor disease. The 
optimal treatment of these patients with biochemical recurrence is an issue of 
ongoing controversies. In the case of a slow PSA rise years after prostatectomy 
and low risk features in the prostatectomy sample, a local recurrence is most 
probable. Patients suspected to have local recurrence are generally treated with 
radiotherapy. Patients with PSA values >0.5 ng/ml, a fast increase of serum 
PSA and high risk features in prostatectomy are at increased risk of having a 
systemic disease relapse [92]. The gold-standard for metastatic disease is 
antihormonal treatment. Current imaging methods are often unable to detect 
systemic disease even though the tumor might indeed have spread 
systematically. The optimal moment for starting hormone deprivation therapy in 
patients with biochemical relapse but no disease spots detected in imaging is 
critically discussed, since there is no evidence that an early beginning of 
hormone deprivation treatment improves overall survival. Moreover, the side 
effects of antihormonal treatment may significantly impact the patients’ quality of 
life and therefore should be taken into account when choosing this treatment 
option.  
Cancer is considered to be associated with significant changes in the immune 
system. Moreover, it is broadly accepted that modulation of the immune system 
might be a promising approach to modify disease biology. Vaccination-based 
therapies have shown outcome improvements in various malignancies including 
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prostate cancer. Sipuleucel-T is an autologous APC-based vaccine approved 
for the treatment of castration resistant prostate cancer. As many of the 
vaccination based treatments have only limited side effects, it has been recently 
discussed whether vaccination based treatment might be a promising option for 
the treatment of biochemical relapse of prostate cancer. At the University 
hospital of Tuebingen, a phase I/II trial was conducted evaluating the 
effectiveness of a multi-peptide vaccination for patients presenting with 
biochemical recurrence but no visible disease recurrence. The aim of the 
present study was to compare the oncologic outcome of those patients who 
received vaccination within the trial with the outcome of the patients screened 
for the trial but not receiving vaccination.  
In total, 101 patients with biochemical recurrence after prostatectomy were 
included in the study. Of these, 36 patients received vaccination treatment 
within the phase I/II trial. The proportion of patients with a cancer specific 
treatment between prostatectomy and screening for the trial was 36.6%. The 
five year recurrence free survival and overall survival rates were as high as 
70.7% and 95.8%. In patients receiving vaccination treatment, the time to 
clinical disease recurrence tended to be longer compared to the control group 
not receiving vaccination treatment. Moreover, the time to first cancer-specific 
therapy after screening for the study was significantly longer in those patients 
receiving vaccination treatment. No differences in overall survival and cancer 
specific survival were observed between the two groups after a median follow-
up of 64 months. The time to initiation of androgen deprivation therapy did not 
differ between the two groups in the primary analysis and demonstrated a slight 
and significant improvement for the vaccinated patients in the re-analysis at 
March 2015, .    
 
The minority of patients with biochemical recurrence experiences clinical 
disease relapse and cancer specific death 
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One of the major observations of the present study is that the proportion of 
patients developing clinical recurrence, metastasis or cancer related death after 
biochemical recurrence is relatively low regardless of the treatment offered 
following biochemical recurrence. This is in accordance with other studies 
showing low rates of clinical recurrence and cancer specific mortality in patients 
with biochemical recurrence after radical prostatectomy. Roberts et al. did a 
retrospective analysis of 2809 patients who underwent RP between 1987 and 
1993. PSA values were routinely measured after surgery; the clinical disease 
course was assessed through bone scan, DRE and ultrasound. They observed 
that 31% of the patients had a biochemical recurrence. For these patients the 
systemic progression-free survival rate was 94% after 5 years and 91% after 10 
years from the time of biochemical relapse [152].  Freedland et al. performed a 
retrospective analysis of 379 patients with biochemical recurrence after RP. 
They observed a 10-year cancer specific mortality rate of 27% [153]. In contrast 
to the above mentioned studies our cohort included a significant proportion of 
patients having received adjuvant cancer specific treatment. The outcome of 
patients with biochemical recurrence after adjuvant radiation therapy has been 
reported in two studies. In a cohort of 134 men with biochemical recurrence 
following RP plus adjuvant radiation 31.5% experienced systemic progression 
and 14.2% died of prostate cancer after a median follow-up of 13.1 years [154]. 
Abdollah et al. observed a 10-year cancer specific mortality rate of 21.5% in a 
cohort of 336 patients with biochemical recurrence after adjuvant radiotherapy 
and RP [155].  These studies showing a favorable outcome after adjuvant 
therapy following prostatectomy concur with the results of the present study.  
 
Time to clinical recurrence is delayed in patients receiving multipeptide 
vaccination 
In the present study, the time to clinical recurrence was longer in patients who 
received multipeptide vaccination compared to the control group. This was 
statistically significant in the group of patients who did not receive any additional 
treatment between prostatectomy and screening. We consider this group to be 
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more homogenous than the remainder of the patients. The delayed time to 
clinical recurrence indicates that radiological non-visible tumor foci causing an 
increase of the serum PSA are affected by vaccination treatment which may 
cause growth inhibition. The fact, that the time to occurrence of distant 
metastases was not statistically different between the vaccinated patients and 
the non-treated control group indicates that the effect of vaccination might be 
different on cancer cells residing in the former surgical bed than disseminated 
tumor cells. However, several studies have indicated that disseminated tumor 
cells in the blood stream or bone marrow are also responsible for local 
recurrence [156, 157]. Therefore, this statement has to be considered with 
caution.   
Most of the previous vaccination trials for prostate cancer have been conducted 
with CRPC patients and the clinical endpoint of time to progression was not 
affected by the treatment. All three trials that led to the approval of sipulecuel-T 
did not show any improvement in TTP for the vaccinated group compared to the 
placebo group [138, 139]. The phase II PROSTVAC-VF trial showed equal 
results, since it did not meet its primary endpoint, a prolongation of TTP [144]. 
The effect of vaccination in these trials was observed through the improvement 
in survival endpoints such as overall survival and cancer specific survival (see 
discussion below). It must be said that tumor dynamics while progression of the 
disease are different between CRPC patients and patients who have recently 
experienced biochemical tumor relapse, so the comparability of the data 
between the sipuleucel-T and PROSTVAC-VF studies and our study is limited.   
. 
Effect of vaccination on time to subsequent cancer specific therapy 
In our study, patients receiving no vaccination treatment were set earlier on a 
further anti-cancer treatment than patients receiving vaccination. In the primary 
analysis including follow up data until 2012, this difference was statistically 
significant for the whole cohort only when applying the Wilcoxon test for 
analyzing the Kaplan Meier estimates. In this case the Wilcoxon test is more 
appropriate than the log-rank test since the crossover of the Kaplan-Meier 
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curves indicates a non-constant event rate in both groups [158]. In the 
secondary analysis the significant this difference persisted comparing mean 
time span to the subsequent therapy. 
There are several potential causes for the delay of subsequent therapies. The 
first reason could be that the shorter time to clinical recurrence may have led to 
earlier initiation of an anticancer treatment in non-vaccinated patients. The 
majority of patients received either hormone deprivation therapy or radiation 
therapy as first subsequent anticancer treatment. The fact that the time to 
hormone deprivation treatment was not significantly affected by vaccination 
indicates that vaccination may have rather delayed the first treatment in patients 
receiving radiation treatment. This is in accordance with the above mentioned 
observation that vaccination seems to have a different effect on local and 
systemic recurrences. Regardless of these facts, the secondary analysis 
showing a significant difference between the two groups after more than two 
years suggests a profit of the patients from the vaccination therapy. This was 
observed in the first months of follow-up reflected by the significant difference 
as measured by the Breslow test, which is more sensitive to detect early 
differences in survival between the groups while the log-rank test did not show a 
significant difference. 
However, the delay in the time to subsequent therapies may be also caused by 
differing criteria used by the treating urologists to initiate another treatment in 
patients already receiving vaccination treatment and those without vaccination 
treatment. The optimal time point of both radiation therapy and hormone 
deprivation therapy in patients with relapse after prostatectomy is still a current 
topic of controversy [109]. Whereas some patients receive treatment at a low 
level of PSA, others are set on treatment only in the case of visible recurrence 
or metastases. In our study, five patients of the control group received hormone 
deprivation therapy immediately after screening failure for the clinical trial. Other 
patients received hormone therapy only several months after screening, even 
though the performance status and disease stage did not differ significantly 
from the other patients. The vaccination treatment may have led to a later 
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initiation of radiation or antihormonal therapy as the treating urologists may 
have already considered the vaccination as a treatment with an anti-cancer-
specific effect, although it was applied in the framework of a clinical trial and 
although the trial was designed not to affect further indicated treatments. To 
partially control for this bias, we performed an analysis where we compared the 
time to next therapy from last vaccination (in the case of vaccinated patients) 
and time to next therapy from screening (in the case of non-vaccinated 
patients). Since in this analysis we observed no difference between both 
groups, this might indicate that the application of vaccination treatment may 
indeed have influenced the decision-making process regarding subsequent 
treatments.  
Hence, the initiation of another treatment has to be considered as an endpoint 
that is strongly influenced by individual differences in the management of 
relapse of prostate cancer. As mentioned above, criteria to start a subsequent 
treatment (including radiation and hormone deprivation therapy) vary broadly 
between different urologists.  
 
Effect of vaccination treatment on time to hormone deprivation therapy 
We did not observe a significant difference in the intervals between screening 
and initiation of hormone deprivation therapy in any of the two groups. The 
secondary analysis demonstrated a significant difference between the groups if 
the Breslow test was used, which is more sensitive to detect early differences. 
Nevertheless in the long-term the mean time to the initiation of ADT was not 
different between the groups. This concurs with the observation that time to 
occurrence of metastases did not differ between vaccinated and non-vaccinated 
patients, since the occurrence of metastases generally serves as a trigger for 
initiation of antihormonal treatment [159]. As previously mentioned, there is no 
clear evidence showing that a treatment delaying initiation of ADT affects 
overall survival of patients with prostate cancer [61]. Furthermore, hormone 
deprivation therapy is generally considered as a treatment with a negative 
impact on the quality of life of patients with prostate cancer. The most important 
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side effects include loss of libido, hot flushes, fatigue, osteoporosis and 
metabolic disorders [63]. Therefore, there is an important unmet need for 
therapies potentially delaying or replacing hormone deprivation therapy without 
impairing oncologic outcome.  The endpoint of time to initiation of hormone 
deprivation treatment should not be considered as a strong surrogate marker for 
oncologic outcome as the optimal time point for initiation of antihormonal 
treatment is a controversial issue in urology.  
 
Effect of vaccination treatment on overall and cancer specific survival  
Our results indicate that multipeptide vaccination does not lead to improved 
cancer-specific and overall survival in patients with biochemical recurrence. 
This differs to other trial results in prostate cancer observing a significant 
improvement of survival in patients with CRPC. The IMPACT trial 
(Immunotherapy for Prostate Adenocarcinoma Treatment) enrolled 512 
asymptomatic CRPC patients. Patients were either treated with sipulecuel-T or 
placebo in a ratio of 2:1. The primary end point was overall survival, which was 
significantly improved in the sipulecuel-T group (sipuleucel-T 25.8 months vs. 
21.7 for placebo). A phase II, double-blind randomized study for PROSTVAC-
VF was conducted with 122 CRPC men. Although the study failed to meet its 
primary endpoint of prolonged time to progression, an improvement in the OS 
for the PROSTVAC-VF group versus the placebo group could be observed 
(median OS 24.5 vs. 16.0 months)  
There are several potential reasons for the discrepancy of the results of our 
study and these trials. First, in our study the follow-up was limited and the 
overall rate of deaths was low. This is in accordance with prior studies showing 
low cancer-specific mortality rates in patients with biochemical relapse. We 
cannot exclude that after a longer follow-up and an increased rate of events the 
survival differs between both groups. Second, the clinical setting was different in 
our setting compared to other studies. Phase II and III trials for Sipuleucel-T and 
Prostvac-VF were all performed in patients with castration resistant prostate 
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cancer. Castration resistant prostate cancer is considered to have significant 
biologic differences compared to castration sensitive prostate cancer (CSPC). 
Castration resistant cancer cells have been shown to exhibit various alterations 
compared to castration sensitive cells [160]. Although to date no evidence 
exists showing differences in tumor-immunology relevant aspects between 
CRPC and CSPC, the results of the present study, among other studies, 
indicate that CSPC might be more suitable for application of immune-system-
targeting treatments. 
The observed differences in survival benefits in the present study and other 
phase II/III trials may be also related to different efficacies of different 
vaccination strategies.  
 
Differences in immunotherapy based approaches for prostate cancer.  
Although considerable advances have been made in the field of tumor 
immunology in the last decade, the optimal application of tumor vaccines is still 
unclear. From what is known until now though, it seems clear that when it 
comes to cancer vaccines it is of the outmost importance to select adequate 
immunological targets in order to create a sufficiently large immune response 
and achieve long term immunological memory [161] to accomplish a positive 
effect. In the current study, a multipeptide vaccination was applied. The 
peptides composing this vaccine were carefully chosen on the basis that these 
epitopes would most likely create an adequately large, PC specific immune 
response and that the combination would counteract possible tumor evasion 
mechanisms. Because the majority of the peptides were HLA-A2-restricted 
epitopes, the vaccinated patients had to be HLA A2 positive. This limits the 
applicability of the peptide vaccine, since only estimated 40 to 50% of the 
german population are HLA A2 positive. The present phase I/II study had the 
evaluation of the drug tolerance and immune response as primary endpoint  
and PSA response as secondary endpoint. The multipeptide vaccine was well 
tolerated with only two grade 3 adverse effects. 
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The personalized peptide vaccine from Noguchi et al. showed positive results 
regarding progression-free survival and overall survival after the first round of 
treatment. Also, there was a significant immune response after the vaccination 
treatment measured by IgG titers and IFN-ɣ release essay, though there is not a 
clear correlation to a clinical benefit. Treating the patients only with those 
peptides which caused a strong immune reaction during pre-vaccination is 
probably crucial for the patients to achieve an efficient immune response. 
However, it makes the production of this vaccine, similar to sipuleucel-T, costly 
and more difficult. This study was conducted with CRPC patients so the 
question about how CSPC patients would respond remains open. The study 
was also limited to HLA A2 and HLA A24 patients, since the peptides were 
restricted to these HLA molecules respectively, which also reduces the number 
of patients that can be treated.  
Sipuleucel-T treatment uses PAP loaded tumor cells which induce a tumor 
targeted T cell response. The immune response induced by this treatment was 
measured by titers of antibodies against the antigen PA2024. The patients 
treated with the vaccine showed elevated antibody titers and higher T-cell 
proliferation rates than the patients in the placebo group [138]. Of note, there 
was no correlation between survival and T-cell response. Sipuleucel-T was 
approved by the FDA since it was shown to provide a benefit in OS for the 
treated group and was well tolerated by the patients. However, several issues 
still have to be considered while using it as a standard therapy. The 
identification of patients with clinical benefit is difficult as patients continued to 
have disease progression. Moreover, the optimal timing for further therapies 
following Sipuleucel-T treatment is challenging due to the lack of surrogate 
parameters of clinical benefit. The target group of the trial was CRPC patients 
and therefore it is unknown how patients in a different disease stage would 
react. However, a tendency towards benefit could be observed, independent 
from Gleason Score and other risk factors, suggesting sipuleucel-T could be 
applicable for other patients as well. Furthermore, it is an individualized therapy 
which makes the production expensive and time consuming. 
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The combination in the PROSTVAC-VF treatment presents several advantages 
in promoting tumor immunity: first, the vaccinia virus is immunogenic itself, thus 
contributing to create an immune response. Second, when host’s cells get 
infected, necrosis causes them to release pro-inflammatory signals and PSA 
which is taken from DCs to be processed and presented on their surface. The 
pro-inflammatory substances released also help to activate DCs enhancing the 
immune system’s reaction. Furthermore, these vectors present the benefit of 
being able to deliver a great amount of target loads and are also relatively easy 
to produce and manipulate [162]. The vaccine creates an immune response 
measured by an increase of PSA specific T-cells. The toxicity is low, presenting 
little adverse effects. Compared to sipulecuel-T, it presents the advantage that 
the manufacturing process of PROSTVAC-VF is much less complicated, since it 
is not an individualized vaccine. The results of the ongoing phase III trial should 
be able to provide more information about the effects of PROSTVAC-VF on PC 
[146]. 
The results from the phase I/II trial with a DNA based vaccine encoding PAP 
and pro-inflammatory agents showed an antibody and T-cell response against 
PAP [147]. Also a deceleration of PSA rate rise could be observed. Even 
though it was a small group of patients, the data demonstrates the vaccine 
caused an immune response in the patients. A long-term follow-up of the 
patients included in the phase I/II trial or a larger trial with this vaccine could 
probably provide further information. 
GVAX is a mixture of two allogeneic prostate tumor cell lines treated to secrete 
GM-CSF. They do not proliferate since they are previously treated with 
radiation. GVAX presents the advantage that the vaccine can be produced in 
large quantities, making the manufacturing costs lower and thus increasing the 
number of patients that can be treated. Because it contains whole tumor cells, 
the number of tumor antigens delivered (known and unknown prostate cancer 
tumor antigens) is considerable. This should provide a major advantage 
compared to the other vaccines, since, provided GVAX succeeded in creating 
an immune response, the variety of activated T- and B-cells would be very 
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large. Also, it is believed that with a larger variety of tumor antigens, the 
possibilities for the tumor to develop evasion mechanisms from the immune 
system are reduced [163]. However, since both studies testing the effect of 
GVAX were stopped prematurely, no definite statement can be made about the 
immunologic effectiveness of this treatment [141]. 
Immunotherapy for PC has been showing promising results and it seems that 
this approach should be further encouraged and analyzed in earlier disease 
stages instead of CRPC patients. However, the results of the present study 
showing a low number of cancer related deaths after a mean follow up of more 
than 5 years indicate that future studies using immunologic therapies in this 
stage of disease require a follow-up of at least 10 years. Alternatively, reliable 
surrogate parameters for survival improvement in patients treated with 
vaccination therapy have to be identified.  As the rate of patients with 
radiologically detectable disease is lower in earlier stages of disease, the use of 
radiologic response is questionable. PSA has been assessed in many studies; 
however, to date there is a lack of data on correlation of PSA response and 
overall survival in patients treated with vaccination. Immunologic monitoring of 
patients in these trials provides a promising alternative but still remain a 
challenge, since there are no standardized procedures to follow immune cells’ 
activities after treatment.  
 
Future of immunobased therapies in recurrent prostate cancer 
The improvement of overall survival in patients with prostate cancer by 
application of Sipuleucel-T has provided a proof of principle showing that 
immunobased therapies can have a significant benefit for patients with CRPC. 
Several other studies have supported the concept of prostate cancer as a tumor 
susceptible to modulations of the immune system. These observations have 
raised the hope that the application of immunotherapies may be even more 
promising in earlier stages of prostate cancer as the number of tumor cells the 
immune system has to cope with is lower. In fact, animal studies indeed show 
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that vaccination therapies show better results when the tumor burden is smaller 
[164]. However, to date no clear evidence exists that modulation of the immune 
system in the context of castration sensitive prostate cancer provides clinical 
benefit. The results of the present study should encourage further research on 
immunotherapies in the context of early disease relapse. Although the trial 
which formed the basis of the present study was not designed to detect a 
benefit on cancer-related outcome, the observed differences in time to 
recurrence should encourage the initiation on further trials addressing this 
issue. To investigate both recurrence-free and overall survival, these trials 
should include regular imaging, clear criteria for disease progression and a long 
term-follow-up of the patients. If immunotherapy based approaches should 
indeed demonstrate a significant benefit on oncologic outcome, the application 
of hormone deprivation therapy in recurrent prostate cancer would have to 
undergo complete re-evaluation and additional trials including different 
sequences of vaccination and hormone deprivation therapy would have to be 
performed.   
 
Limitations of the study 
The present study exhibits various major limitations. First, the clinical trial 
forming the basis of this study was not designed to evaluate the efficacy of 
multipeptide vaccination on cancer-specific outcome as its primary endpoint. 
The follow-up of patients varied broadly from patient to patient in both groups. 
Also, no regular imaging schedules were applied neither for patients included in 
the trial nor the control patients. As the patients’ treating urologists were 
responsible for the follow-up, the differences observed between the two groups 
might be due to differences in follow-up schedules. The group of patients 
screened for the study was quite heterogeneous with a high proportion of 
patients having received additional cancer-specific therapies between 
prostatectomy and vaccination. Therefore, this cohort might not be 
representative for a typical cohort of patients with biochemical recurrence. The 
different therapies performed between prostatectomy and screening for the 
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study may have a major influence on the study outcome. To control for this bias, 
sub-analyses in patients without any cancer-specific therapy between 
vaccination and screening for the study were performed. The homogenicity of 
the vaccinated cohort was limited from the beginning since different adjuvants 
were applied during vaccination as determined by the study protocol to analyze 
the induction of the immune response. This however served to the purpose of 
assessing the impact of these adjuvants, so the heterogeneity of the group was 
taken into account. The follow-up of the study was limited preventing the power 
of the study for evaluating the effect of vaccination on survival. 
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Summary 
 
PC is the most common cancer entity in men in Germany. The broad use of 
PSA screening has led to a significant increase of tumors diagnosed in a 
localized stage. Many of these patients undergo surgical therapy or radiation, 
although there is no clear evidence that this has a significant impact on the 
course of disease. Both surgery and radiotherapy are performed with a curative 
intention. However, a significant proportion of patients experiences biochemical 
disease recurrence. The optimal treatment of these patients with biochemical 
recurrence but no evidence of clinical recurrence is discussed controversially. A 
peptide vaccination against tumor specific surface antigens has shown efficacy 
in several tumor entities. Whether this approach might provide benefit for 
patients with biochemical relapse after prostatectomy is unclear. The aim of the 
present study was to evaluate the clinical outcome of patients taking part in a 
clinical trial evaluating the efficacy of a multipeptide vaccination for the 
treatment of patients with biochemical relapse. We analyzed data of 101 
patients with PC who underwent RP and had a biochemical disease recurrence. 
36 patients were treated with a multipeptide vaccination therapy and 65 served 
as a control group.  
We observed that in patients treated with vaccination therapy, the time to 
clinical recurrence tended to be longer compared to non-vaccinated patients. 
Moreover, we observed that the first non-vaccination therapy could be delayed 
in the group of patients receiving vaccination therapy. We observed no impact 
of vaccination therapy on cancer-specific and overall survival. The time to 
initiation of hormone deprivation therapy was not delayed significantly by 
peptide vaccination.  
The present study is the first evaluating a multipeptide vaccination for the 
treatment of biochemical relapse in patients with prostate cancer. In contrast to 
prior studies in other malignancies, the vaccination resulted in a significant 
delay of clinical recurrence whereas overall survival, an endpoint which is most 
frequently affected by immunization based therapies in cancer, was not 
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changed. These results implicate that immune therapy might have a short to 
mid-term effect on tumor dynamics in patients with biochemical relapse but 
does not significantly affects the long-term course of the disease. Although the 
mechanisms potentially leading to the delay of clinical recurrence are unclear, 
the results of the present study encourage further investigations on the use of 
immunotherapy in patients experiencing biochemical relapse after treatment 
with a curative intention.  
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Zusammenfassung 
 
Das Prostatakarzinom ist die häufigste Krebserkrankung bei Männern in 
Deutschland. Die breite Verwendung des Serum PSA  als Screening Methode 
hat zu einer signifikant erhöhten Inzidenz von  Tumoren, die in einem 
lokalisierten Stadium entdeckt werden, geführt. Viele dieser Patienten werden 
chirurgisch oder mit Strahlentherapie behandelt, obwohl es keine klaren 
Hinweise darauf gibt, dass diese Therapieverfahren einen erheblichen Einfluss 
auf den Krankheitsverlauf haben. Sowohl  radikale Prostatektomie als auch 
Bestrahlung werden mit kurativer Intention durchgeführt. Allerdings erlebt ein 
signifikanter Anteil der Patienten ein biochemisches Rezidiv im Verlauf der 
Erkrankung. Die optimale Behandlung von Patienten mit biochemischen Rezidiv 
ohne Hinweise auf ein klinisches Rezidiv wird kontrovers diskutiert. Eine 
peptidbasierte Impfung gegen tumorspezifische Oberflächenantigene hat für 
mehreren Tumorentitäten eine gute Wirksamkeit gezeigt. Ob dieser Ansatz 
einen Nutzen für Patienten mit einem biochemischen PSA Rezidiv hat, ist 
unklar. Das Ziel der vorliegenden Studie war die Untersuchung des 
Krankheitsverlaufs von Patienten, die an einer Multipeptidvakzinierungsstudie 
teilgenommen haben, um einen möglichen Vorteil dieser Therapie für Patienten 
mit biochemischem Rezidiv zu beurteilen. Wir analysierten Daten von 101 
Patienten mit PC, die nach radikaler Prostatektomie einen PSA Rezidiv erlebt 
haben. 36 Patienten wurden mit einer Multipeptid-Vakzinierungstherapie 
behandelt und 65 dienten als Kontrollgruppe. 
 
Das mediane Follow-up der Studie betrug 64 Monate. Die Zeit zum klinischen 
Wiederauftreten der Erkrankung war  für die Patienten in der 
Vakzinierungsgruppe im Vergleich zu der Kontrollgruppe signifikant verlängert. 
Außerdem konnte beobachtet werden, dass die Zeit bis zur nächsten 
Prostatakarzinom spezifischen Therapie in der Gruppe der geimpften Patienten 
verzögert werden konnte. Die Zeit zur Einleitung einer antihormonellen 
Therapie wurde durch die Vakzinierung nicht signifikant verzögert. Die 
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Vakzinierungstherapie zeigte auch keinen signifikanten Einfluss auf das 
krebsspezifische Überleben oder auf das Gesamtüberleben. 
 
Diese Studie ist die erste, die die Wirkung einer Multipeptidvakzinierung bei 
Patienten mit biochemischen Rezidiv analysierte. Im Gegensatz zu früheren 
Studien in anderen Tumorerkrankungen, führte die Impfung zu einer 
erheblichen Verzögerung des klinischen Rezidives, wohin Gesamtüberleben, 
ein Endpunkt, der am häufigsten zur Evaluierung von Immuntherapien bei 
Malignomen benutzt wird, nicht verändert wurde. Diese Ergebnisse deuten 
darauf hinaus, dass Immuntherapie eine kurze bis mittelfristige Wirkung auf die 
Tumordynamik bei Patienten mit biochemischen Rezidiv haben könnte. Ein 
Hinweis für einen Einfluss auf den  langfristigen Verlauf des Prostatakarzinoms 
liegt bisher nicht vor. Obwohl die Mechanismen, die möglicherweise zur 
Verzögerung des klinischen Rezidiv führten, unklar sind, sollten die Ergebnisse 
dieser Studie das Interesse für Immuntherapien bei Patienten mit einem PSA 
Rezidiv wecken und die Forschung in diesem Bereich fördern.  
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